CHICAGO, July 3, 2014 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includethe Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), MannKind Corporation (Nasdaq:MNKD-Free Report), Auxilium Pharmaceuticals (Nasdaq:AUXL-Free Report), QLT Inc. (Nasdaq:QLTI-Free Report) and AbbVie (NYSE:ABBV-Free Report).
Today, Zacks is promoting its 'Buy' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
It was an eventful week for the biotech sector - highlights included FDA approval for a diabetes product and highly-awaited pivotal phase III data on a cystic fibrosis combination. Acquisitions also made it to the headlines with companies continuing to eye deals that will lower tax rates. Major stocks were up last week with the NASDAQ Biotechnology Index gaining 3.04%.
Recap of the Week's Most Important Stories
1. Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report) was a major gainer with shares shooting up 40.4% on highly-awaited phase III data on a combination of Kalydeco (ivacaftor) and lumacaftor for cystic fibrosis patients. With Vertex deciding to exit its hepatitis C franchise, the company is banking on the cystic fibrosis franchise for growth. The phase III data came at the right time and should allow the company to file for approval by year end (read more: www.zacks.com/stock/news/138039/vertex-pharma-skyrockets-on-cystic-fibrosis-drug-trial-results).
2. It proved to be third time lucky for MannKind Corporation (Nasdaq:MNKD-Free Report) with the company finally gaining FDA approval for its diabetes product, Afrezza. Afrezza's approval is a major milestone for MannKind as it is the first approved product in the company's portfolio (read more: http://www.zacks.com/stock/news/138551/mannkinds-afrezza-approval-a-keymilestone).
3. Auxilium Pharmaceuticals (Nasdaq:AUXL-Free Report), which is going through a challenging period with Testim expected to record a significant drop in 2014 revenues, has decided to merge with Canada-based QLT Inc. (Nasdaq:QLTI-Free Report). The company is looking to benefit from cost synergies and lower taxes (read more: http://www.zacks.com/stock/news/138360/auxilium-and-qlt-to-merge-on-tax-saving-attractions).
4. AbbVie (NYSE:ABBV-Free Report) provided additional details on its proposal to acquire Shire even though Shire has refused AbbVie thrice. The acquisition, if it goes through, would not only boost AbbVie's product portfolio and pipeline, the company would also benefit from a globally competitive tax rate (read more: http://www.zacks.com/stock/news/138236/shire-snubs-abbvie-offer-again-favorable-ruling-for-).
Today, Zacks is promoting its 'Buy' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on VRTX - FREE
Get the full Report on MNKD - FREE
Get the full Report on AUXL - FREE
Get the full Report on QLTI - FREE
Get the full Report on ABBV - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
SOURCE Zacks Investment Research, Inc.
